These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38112434)

  • 1. Reply: 'From NAFLD to MASLD: Promise and pitfalls of a new definition' †.
    Rinella ME; Castro Narro GE; Krag A; Terrault N; Newsome PN
    Hepatology; 2024 Feb; 79(2):E16-E17. PubMed ID: 38112434
    [No Abstract]   [Full Text] [Related]  

  • 2. From NAFLD to MASLD: Promise and pitfalls of a new definition †.
    Cusi K; Younossi Z; Roden M
    Hepatology; 2024 Feb; 79(2):E13-E15. PubMed ID: 38112428
    [No Abstract]   [Full Text] [Related]  

  • 3. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease.
    Loomba R; Wong VW
    Aliment Pharmacol Ther; 2024 Jan; 59(2):150-156. PubMed ID: 38153279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can we use old NAFLD data under the new MASLD definition?
    Song SJ; Lai JC; Wong GL; Wong VW; Yip TC
    J Hepatol; 2024 Feb; 80(2):e54-e56. PubMed ID: 37541393
    [No Abstract]   [Full Text] [Related]  

  • 5. Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD.
    Fukunaga S; Mukasa M; Nakano D; Tsutsumi T; Kawaguchi T
    Clin Mol Hepatol; 2024 Jan; 30(1):121-123. PubMed ID: 38044039
    [No Abstract]   [Full Text] [Related]  

  • 6. Changing from NAFLD to MASLD: The new definition can more accurately identify individuals at higher risk for diabetes.
    He L; Zheng W; Qiu K; Kong W; Zeng T
    J Hepatol; 2024 Feb; 80(2):e85-e87. PubMed ID: 37827469
    [No Abstract]   [Full Text] [Related]  

  • 7. Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD.
    De A; Bhagat N; Mehta M; Taneja S; Duseja A
    J Hepatol; 2024 Feb; 80(2):e61-e62. PubMed ID: 37558135
    [No Abstract]   [Full Text] [Related]  

  • 8. [Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)].
    Canivet CM; Faure S
    Rev Med Interne; 2024 Jan; 45(1):41-47. PubMed ID: 38158295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MASLD vs. NAFLD: A better definition for children with obesity at higher risk of kidney damage.
    Di Sessa A; Guarino S; Umano GR; Miraglia Del Giudice E; Marzuillo P
    J Hepatol; 2024 Feb; 80(2):e87-e89. PubMed ID: 37890724
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
    Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
    J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease.
    Rinella ME; Sookoian S
    J Lipid Res; 2024 Jan; 65(1):100485. PubMed ID: 38103785
    [No Abstract]   [Full Text] [Related]  

  • 12. Waiting for the changes after the adoption of steatotic liver disease.
    Yoon EL; Jun DW
    Clin Mol Hepatol; 2023 Oct; 29(4):844-850. PubMed ID: 37670441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of a questionnaire for assessing the relationship between eating behavior and steatotic liver disease among Japanese male young adults.
    Miwa T; Tajirika S; Hanai T; Imamura N; Adachi M; Horita R; Fukao T; Shimizu M; Yamamoto M
    Sci Rep; 2024 Jan; 14(1):2194. PubMed ID: 38273030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD.
    Ratziu V; Boursier J;
    J Hepatol; 2024 Feb; 80(2):e51-e52. PubMed ID: 37543307
    [No Abstract]   [Full Text] [Related]  

  • 15. MASLD screening and diagnostic algorithms are interchangeable with existing NAFLD literature.
    Arora U; Biswas S; Aggarwal S; Duseja A; Shalimar
    J Hepatol; 2024 Feb; 80(2):e89-e91. PubMed ID: 37925079
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply: NAFLD, MAFLD, or MASLD? Cut the Gordian knot with "Ludwig disease".
    Newsome P; Rinella ME; Lazarus JV; Terrault N
    Hepatology; 2024 Jan; 79(1):E5-E6. PubMed ID: 37651218
    [No Abstract]   [Full Text] [Related]  

  • 17. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
    Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
    Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steatotic liver disease, MASLD and risk of chronic kidney disease.
    Bilson J; Mantovani A; Byrne CD; Targher G
    Diabetes Metab; 2024 Jan; 50(1):101506. PubMed ID: 38141808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials.
    Yeh ML; Yu ML
    Clin Mol Hepatol; 2023 Oct; 29(4):969-972. PubMed ID: 37718552
    [No Abstract]   [Full Text] [Related]  

  • 20. [NAFLD renaming to MAFLD, MASLD: background, similarities, differences, and countermeasures].
    Fan JG; Li XY
    Zhonghua Gan Zang Bing Za Zhi; 2023 Aug; 31(8):789-792. PubMed ID: 37723058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.